Your Body Can't Convert Omega-3s to DHA. Here's the Genetic Reason.

FADS1 encodes delta-5 desaturase, an enzyme responsible for the final elongation step in converting short-chain omega-3 (ALA) into EPA and ultimately DHA. Think of it as the last gatekeeper in a multi-step assembly line. If FADS1 activity is reduced, ALA piles up on one side of the gate while EPA and DHA fail to accumulate on the other side. You end up with functional omega-3 deficiency in your cells even though your diet includes plenty of ALA.

Roughly 30 to 40 percent of the population carries the rs174537 variant in FADS1, which is strongly associated with reduced enzyme activity. People with this variant produce 30 to 50 percent less delta-5 desaturase activity, which directly reduces EPA and DHA synthesis from plant-based omega-3s. Your body spends extra metabolic energy trying to compensate, and still comes up short. Standard omega-3 supplements (based on ALA content) simply don’t work for you because your bottleneck is the enzyme, not the substrate.

You notice this first in your brain. Fuzzy thinking. Difficulty concentrating. Mood feels heavy or unstable. Your skin is dry despite moisturizer. Your joints ache. Your triglycerides are higher than they should be for your diet. These are all signatures of DHA insufficiency. When you switch from ALA-based supplements to preformed EPA/DHA (from fish, algae, or EPA/DHA-specific supplements), the fog lifts within two to four weeks.

FADS2 encodes delta-6 desaturase, the enzyme that catalyzes the very first step of ALA conversion. This is the rate-limiting enzyme for the entire pathway. If FADS2 activity is low, very little ALA ever gets transformed into the intermediate compounds that eventually become EPA and DHA. It’s like having a bottleneck at the entrance to the assembly line. No matter how much ALA you consume, only a trickle makes it through the first transformation.

Approximately 30 to 40 percent of the population carries a variant in rs1535 (FADS2), which is associated with significantly reduced delta-6 desaturase activity. Carriers of the low-activity allele show 30 to 50 percent reduction in the first step of omega-3 conversion, which cascades into severely impaired EPA and DHA production. This effect is especially pronounced if you also carry FADS1 variants, because both enzymes must work. If both are compromised, your DHA synthesis may drop by 70 percent or more.

You experience this as persistent fatigue despite adequate sleep, difficulty concentrating, poor mood regulation, and a feeling that your nervous system is “misfiring.” Your skin may be dry and inflamed. Your immune system feels sluggish. If you’ve tried increasing fish intake or standard fish oil supplementation without relief, FADS2 variants are a leading suspect. Switching to high-dose, preformed EPA/DHA is the only reliable strategy.

PPARG doesn’t directly synthesize fatty acids, but it acts as a master regulator of how your cells take up, transport, and use fats. It’s a nuclear receptor that controls the expression of genes involved in lipid metabolism, glucose control, and insulin sensitivity. When PPARG signaling is impaired, your cells have a harder time moving omega-3 fatty acids across cell membranes and into the mitochondria where DHA is most needed. You can have normal or even high blood DHA levels and still have functional DHA deficiency inside your cells.

The Pro12Ala variant in PPARG is carried by roughly 25 to 30 percent of the population. The Ala allele is associated with improved insulin sensitivity and better cellular uptake of fatty acids, while the Pro/Pro genotype is associated with reduced fatty acid transport capacity into cells. If you carry Pro/Pro, your cells are essentially resistant to the omega-3 you’re consuming. It’s not getting where it needs to go. You end up with a paradoxical situation: normal or high blood omega-3, but symptoms of deficiency.

You notice this as continued brain fog and poor mood despite adequate omega-3 supplementation. Your fasting glucose and triglycerides may be higher than expected. You have difficulty losing weight even when your diet is clean. Your energy crashes quickly after meals. Standard dietary improvements and even high-dose omega-3 don’t fully resolve these symptoms because the problem is cellular transport, not cellular amount.

APOE is the primary transporter protein for DHA and cholesterol in your bloodstream and brain. It packages lipids into particles and escorts them through your circulatory system to cells that need them. Your APOE genotype (E2, E3, or E4) directly influences how much DHA successfully reaches your brain cells and how stable it remains once it gets there. APOE variants also influence neuroinflammation, amyloid clearance, and mitochondrial health. People with APOE4 face particular challenges with DHA retention and processing.

The APOE4 allele is carried by roughly 20 to 25 percent of the population (higher in some ancestry groups). APOE4 carriers show reduced DHA transport into brain tissue and accelerated clearance of DHA from the bloodstream, meaning you need higher DHA intake or supplementation to maintain adequate brain levels. Additionally, APOE4 is associated with higher neuroinflammation and increased vulnerability to cognitive decline, both of which are worsened by DHA insufficiency. APOE4/E4 individuals face the steepest DHA requirements of any genotype.

You experience this as accelerated cognitive decline, poor memory formation, and mood symptoms that are harder to reverse than they should be. Brain fog doesn’t respond as quickly to omega-3 supplementation as it does in APOE3 carriers. You may notice faster fatigue after mentally demanding work. Your sleep quality may be poorer. Standard DHA doses (500-1,000 mg daily) often aren’t sufficient. APOE4 carriers typically need 2,000-3,000 mg daily to achieve cognitive benefits.

MTHFR doesn’t directly control DHA synthesis, but it controls your methylation cycle, which fuels the biochemical reactions required to build and maintain long-chain fatty acids. Reduced MTHFR activity impairs methylation, which reduces the energy available for fatty acid synthesis and increases homocysteine, a metabolite that interferes with omega-3 metabolism. If your methylation cycle is broken, your cells lack the methyl groups and cofactors necessary to efficiently build and preserve DHA even if you’re consuming or supplementing it.

Roughly 40 percent of the population carries the C677T variant in MTHFR, which reduces enzyme activity by 40 to 70 percent. The A1298C variant is carried by approximately 35 percent. People with MTHFR variants have impaired methylation capacity, which reduces their ability to synthesize and maintain DHA, and elevates homocysteine, which directly interferes with omega-3 tissue incorporation. If you carry both C677T and A1298C (compound heterozygous), the effect compounds. Your cellular energy for fatty acid metabolism drops significantly.

You notice this as persistent fatigue that doesn’t improve with sleep, brain fog that remains despite supplementation, mood instability, and poor response to standard omega-3 doses. Your homocysteine may be elevated even with adequate B12 and folate intake. Your energy crashes after meals. Cognitive clarity improves only when you address both your methylation cycle (with methylated B vitamins) and your DHA status simultaneously. Single interventions don’t work.

VDR doesn’t directly control DHA metabolism, but vitamin D is essential for DHA absorption in your gut and for DHA utilization in your cells, particularly in your immune system and nervous system. VDR variants (BsmI, FokI, TaqI) determine how efficiently your cells respond to vitamin D signaling. If your VDR variants reduce receptor sensitivity, your cells are essentially resistant to vitamin D even when your blood levels are adequate. This resistance cascades into impaired DHA absorption, reduced DHA transport across cell membranes, and decreased DHA utilization in the brain and immune tissue.

Approximately 30 to 50 percent of the population carries the BsmI or FokI variants in VDR that reduce receptor sensitivity. People with low-sensitivity VDR variants show reduced intestinal calcium and fat-soluble vitamin absorption, including DHA, even when vitamin D levels are normal or high. Your cells aren’t receiving the signal to absorb and use DHA effectively. You end up with a paradoxical situation: adequate vitamin D supplementation, normal blood D levels, normal blood DHA, but functional deficiency in your tissues.

You experience this as persistent brain fog and poor mood despite supplementing with both vitamin D and omega-3s. Your immune system feels sluggish. Your energy is chronically low. Your skin remains dry and inflamed. Increasing vitamin D supplementation doesn’t improve these symptoms because the problem isn’t the amount of D in your blood; it’s your cells’ ability to receive and respond to the vitamin D signal. Similarly, standard DHA doses don’t fully resolve symptoms because your gut and cells aren’t absorbing it effectively.